两种的晚期胃癌化疗方案的疗效及成本对比研究

Cost Ettectiveness Analysis of two Chemotherapy Schemas on Advanced Gastric Carcinoma

目的:运用药物疗效及经济学方法研究CS辅助化疗与ECF化疗方案,进行成本效果对比分析,为临床合理选用胃癌化疗方案提供参考。方法:选择67例中晚期胃癌患者,随机分为A组(CS,32例)组和B组(ECF组,35例),A组给予CS方案辅助化疗,B组给予ECF方案化疗,3个周期为l疗程,均治疗3个疗程后评价治疗效果及副作用,进行成本效果分析。结果:A组与B组治疗效果比较差异无显著性差异(P>0.05),A组治疗的有较低的相关死亡率,但与B组比较差异无统计学意义(3.13%vs8.57%,P>0.05),A组Ⅲ/Ⅳ度中性粒细胞降低(12.56%vs 37.14%)、Ⅲ/Ⅳ度粒细胞减少性发热(3.13%vs 20.0%)、Ⅲ/Ⅳ度口腔粘膜炎(3.13%vs 22.90%)、肾毒性(15.6%vs 37.10%)、严重低钾血症(6.30%vs 40.0%)的发生率均低于B组(P<0.05)。A组成本较高,并且由于成本增加,有较高的成本效益比。结论:CS方案虽然有较好安全性,但因成本增加,有较高的成本效益比,患者应根据经济能力选择合适的治疗方案。

Objective： To analyze the cost and ettectiveness of two chemotherapy schemas on advanced gastric carcinoma.Methods： 67 cases with advanced gastric carcinoma are randomized into two groups： group A（CS group,32 cases） and group B（ECF group,35 cas-es）,while the group A take CS chemotherapy schema for 3 courses of treatment.The group B take ECF chemotherapy schema for 3 courses of treatment.Analyze the treatment effectiveness,side effect and cost ettectiveness.Results： The treatment effec-tiveness of two chemotherapy schemas has no difference（P0.05）.Group A has lower correlated death rate than group B,but the difference has no sta-tistically significance（P0.05）.The cases in group A have lower rate than group B in Ⅲ/Ⅳ grate neutrophilic granulocyte decline（12.56% vs 37.14%）,febrile（3.13% vs 20.0%）,Ⅲ/Ⅳgrate oral mucositis（3.13% vs 22.90%）,renal toxicity（15.6% vs 37.10%）,severe hypokalemia（6.30% vs 40.0%）（P0.05）;Group A has higher cost and cost ettectiveness than group B.Conclusion： CS chemotherapy schema has better safe reliability,higher cost and cost ettectiveness than group B.The patient should choose suitable chemotherapy schemas depending on economic ability.